6O38 image
Deposition Date 2019-02-26
Release Date 2019-07-24
Last Version Date 2024-10-16
Entry Detail
PDB ID:
6O38
Title:
Structure of a chaperone-substrate complex
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
2.60 Å
R-Value Free:
0.23
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Acinetobacter secreted protease CpaA
Chain IDs:A, B, C, D, E, F
Chain Length:578
Number of Molecules:6
Biological Source:Acinetobacter nosocomialis M2
Polymer Type:polypeptide(L)
Molecule:Type II secretion chaperone CpaB
Chain IDs:G, H, I (auth: K), J (auth: L), K (auth: M), L (auth: N)
Chain Length:178
Number of Molecules:6
Biological Source:Acinetobacter nosocomialis M2
Primary Citation
The structure ofAcinetobacter-secreted protease CpaA complexed with its chaperone CpaB reveals a novel mode of a T2SS chaperone-substrate interaction.
J.Biol.Chem. 294 13344 13354 (2019)
PMID: 31320476 DOI: 10.1074/jbc.RA119.009805

Abstact

Members of the Acinetobacter baumannii-calcoaceticus complex are nosocomial pathogens frequently causing multidrug-resistant infections that are increasing at alarming rates. A. baumannii has become the Gram-negative bacterium with the highest rate of multidrug resistance. As such, it is categorized by the World Health Organization as a critical priority for the research and development of new antimicrobial therapies. The zinc-dependent metalloendopeptidase CpaA is a predominant substrate of the type II secretion system (T2SS). CpaA is also a virulence factor of medically relevant Acinetobacter strains that specifically degrade the human glycoprotein coagulation factor XII and not its deglycosylated form, but the mechanism for this specificity is unknown. CpaB is a membrane-anchored T2SS chaperone that interacts with CpaA and is required for its stability and secretion. Here, we report the crystal structure of the CpaAB complex at 2.6-Å resolution, revealing four glycan-binding domains in CpaA that were not predicted from its primary sequence and may explain CpaA's glycoprotein-targeting activity. The structure of the complex identified a novel mode for chaperone-protease interactions in which the protease surrounds the chaperone. The CpaAB organization was akin to zymogen inactivation, with CpaB serving as a prodomain that inhibits catalytically active CpaA. CpaB contains a C-terminal tail that appears to block access to the CpaA catalytic site, and functional experiments with truncated variants indicated that this tail is dispensable for CpaA expression and secretion. Our results provide new insight into the mechanism of CpaA secretion and may inform the future development of therapeutic strategies for managing Acinetobacter infections.

Legend

Protein

Chemical

Disease

Primary Citation of related structures